Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Extension Study to Evaluate the Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures Who Had Participated in P09-004, a Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study

NCT01191086 is registered in ClinicalTrials.gov with Upsher-Smith Laboratories as lead sponsor.

NCT NCT01191086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01191086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Extension Study to Evaluate the Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures Who Had Participated in P09-004, a Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study
Lead sponsor
Upsher-Smith Laboratories
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2010
Completion date
May 31, 2014
Enrollment
210 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy